- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03430089
Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine
Safety of a Single Dose (Participants Aged 9 Years and Older) or Two Doses Given 28 Days Apart (Participants Aged 6 Months to 8 Years) of the Shenzhen Quadrivalent Influenza Vaccine (Split Virion), Inactivated
This phase I-like, open-label, monocenter, descriptive, single-arm clinical safety study will investigate the Shenzhen quadrivalent influenza vaccine (Shz QIV) in 100 participants aged 6 months and older in China.
Participants aged 9 years or more will receive a single dose of Shz QIV, and participants aged 6 months to 8 years will receive two doses of Shz QIV administered 28 days apart.
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Yunnan
-
Xishuangbanna, Yunnan, China
- Investigational Site 002
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥ 6 months on the day of inclusion
- For participants aged 6 months through 17 years: Informed consent form has been signed and dated by the parent(s) or another legally acceptable representative, if applicable. Additionally an assent form has been signed and dated by the participant if aged 8 through 17 years (based on local regulations) For participants aged 18 years and older: Informed consent form has been signed and dated by the participant
- Participant / Participant and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures
- For participants aged less than 2 years only: Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥ 2.5 kg
Exclusion Criteria:
- Participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. To be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile
- Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination [or the first trial vaccination]) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- Receipt of any vaccine or planned receipt of any vaccine within the period from 4 weeks before study vaccination (or the first study vaccination) to 4 weeks following study vaccination (or the last study vaccination)
- Previous vaccination against influenza with either the study vaccine or another vaccine from the current season
- Receipt of any vaccine or planned receipt of any vaccine within the period from 2 weeks before trial vaccination (or the first trial vaccination) to 2 weeks following trial vaccination (or the last trial vaccination)
- For participants aged 6 to 8 years only: Previous vaccination against influenza vaccine in the past
- For participants aged 9 years and older: Previous vaccination against influenza (in the previous 6 months) with either the trial vaccine or another vaccine
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
- Self-reported thrombocytopenia or known thrombocytopenia as reported by the parent/legally acceptable representative, contraindicating IM vaccination
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Current alcohol abuse or drug addiction
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature ≥ 37.1°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: 6 to 35 months
Shz QIV 0.25 mL, 2 doses
|
Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
|
Experimental: Group 2: 3 to 8 years
Shz QIV 0.5 mL, 2 doses
|
Administered intramuscularly into the deltoid muscle, 28 days apart
|
Experimental: Group 3: 9 to 17 years
Shz QIV 0.5 mL, single dose
|
Administered intramuscularly into the deltoid muscle.
|
Experimental: Group 4: 18 to 60 years
Shz QIV 0.5 mL, single dose
|
Administered intramuscularly into the deltoid muscle.
|
Experimental: Group 5: 61 years and older
Shz QIV 0.5 mL, single dose
|
Administered intramuscularly into the deltoid muscle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of serious adverse reactions or Grade 3 non-serious adverse reactions following vaccination with Shz QIV
Time Frame: Within 28 days after vaccination
|
Number of participants reporting serious adverse reactions and Grade 3 adverse reactions following a vaccination with Shz QIV
|
Within 28 days after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of unsolicited systemic AEs reported in the 30 minutes following vaccination/each and any vaccination
Time Frame: Within 30 minutes after vaccination
|
Within 30 minutes after vaccination
|
Occurrence of solicited (prelisted in the subject diary and the electronic Case Report Form [CRF]) injection site reactions and systemic reactions occurring between D0 and D7 after vaccination/each and any vaccination
Time Frame: Up to 7 days after vaccination
|
Up to 7 days after vaccination
|
Occurrence of unsolicited (spontaneously reported) AEs from D0 to D28 after vaccination/each and any vaccination
Time Frame: Up to 7 days after vaccination
|
Up to 7 days after vaccination
|
Occurrence of SAEs
Time Frame: Up to 56 days after the 1st vaccination
|
Up to 56 days after the 1st vaccination
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FSQ01
- U1111-1174-4615 (Other Identifier: WHO Universal Trial Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on Shz QIV 0.25 mL, 2 doses
-
Kaiser PermanenteCenters for Disease Control and PreventionCompletedInfluenzaUnited States
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Hospital Universitario Ramon y CajalTerminated
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
University Hospitals Cleveland Medical CenterWithdrawnNeonatal Neurobehavior | Breastfeeding OutcomesUnited States
-
Baxalta now part of ShireAlzheimer's Disease Cooperative Study (ADCS)CompletedAlzheimer´s DiseaseUnited States, Canada
-
Pontificia Universidad Catolica de ChileUnknownSurgery | Nerve Block | Anesthetic Toxicity | Anesthetics Complications | Bupivacaine OverdoseChile
-
Bezmialem Vakif UniversityUnknownPostoperative Pain | Postoperative Nausea and Vomiting | Opioid Use
-
University of PennsylvaniaMerck Sharp & Dohme LLC; The Dana Foundation; Kos PharmaceuticalsCompletedEstablished Carotid Atherosclerosis
-
University of Texas Southwestern Medical CenterCompleted